The Patent Finder
RU

The Rockefeller University

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

160 patents currently held

17 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Oct 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
10
Ending by 2030
Oct 2027
Next term end
73
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Sequence Specific Antimicrobials US 10,660,943
The most cited patent in this portfolio, cited by 171 later US patents, top 1% of utility patents granted in 2020 in our data. Protection runs to 2034.
Ends May 2034 · High confidence
Also notable
System and Method for Optical Detection of Skin Disease US 10,182,757
Cited by 81 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2034.
Ends Jan 2034 · High confidence
Also notable
Antibodies Directed Toward the HIV-1 GP120 CD4 Binding Site with Increased Potency and Breadth. US 9,493,549
Cited by 68 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Ends Jul 2032 · High confidence

Formerly held, still cited

Notable
The most cited patent in this portfolio, cited by 383 later US patents, top 1% of utility patents granted in 2017 in our data. Protection runs to 2033. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Ends no later than Dec 2033 · Low confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 3 fees due Nov 21 to 28, 2026 · next Nov 21
  • 3 fees due Dec 2 to 13, 2026 · next Dec 2
  • 2 fees due Jan 4 to 14, 2027 · next Jan 4
  • 2 fees due Feb 27, 2027
  • 6 fees due Mar 8 to 24, 2027 · next Mar 8
  • 1 fee due Apr 27, 2027
    The maintenance fee for Modified RNA Ligase for Efficient 3' Modification of RNA (US 9,169,507) comes due Apr 27, 2027. Unpaid by Oct 27, 2027, it lapses early.
  • 2 fees due May 7 to 28, 2027 · next May 7
  • 4 fees due Jul 9 to 28, 2027 · next Jul 9
  • 8 fees due Sep 5 to 29, 2027 · next Sep 5
  • 1 fee due Nov 19, 2027
    The maintenance fee for Tri-Specific Antibodies for HIV Therapy (US 10,654,943) comes due Nov 19, 2027. Unpaid by May 19, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • Nov 3Assignment recorded on 1 record: Perez-Mitta, Gonzalo and 1 other to The Rockefeller University Recorded Nov 3, 2026, executed Feb 28, 2025. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76608, frame 174.
  • 2 of the patents on this record were granted since Aug 23, 2026
  • 3 terms have ended since Aug 23, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 9,532,980Methods for the Treatment of A-Beta Related Disorders and Compositions Therefor
In force
 · High confidence
In forceHigh confidence
US 9,169,507Modified RNA Ligase for Efficient 3' Modification of RNA
In force
 · High confidence
In forceHigh confidence
US 8,809,022Modified RNA Ligase for Efficient 3` Modification of RNA
In force
 · High confidence
In forceHigh confidence
US 8,470,318Polypeptides with Enhanced Anti-Inflammatory and Decreased Cytotoxic Properties and Relating Methods
In force
 · High confidence
In forceHigh confidence
US 7,846,744Methods of Identifying Anti-Inflammatory Compounds
In force
 · High confidence
In forceHigh confidence
US 11,015,182Chimeric Bacteriophage Lysin with Activity Against Staphylococci Bacteria
In force
 · High confidence
In forceHigh confidence
US 11,827,911Chimeric Bacteriophage Lysin with Activity Against Staphylococci Bacteria
In force
 · High confidence
In forceHigh confidence
US 8,383,370Modified RNA Ligase for Efficient 3` Modification of RNA
In force
 · High confidence
In forceHigh confidence
US 8,703,707Nucleobindin I Variant Protein Compositions and Methods of Use
In force (reinstated)
 · High confidence
In force (reinstated)High confidence
US 9,134,310Methods of Identifying Anti-Inflammatory Compounds
In force
 · High confidence
In forceHigh confidence
10 of 160 patents shown.
Pro members see all 160.
Pro members: see all 160 patents
Also on record, not counted in the 160: 17 patents in force now held by others · 103 patents ended · 73 applications pending · 158 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited